Resolution 57.18 led to three WHO-supported global consultations.
The first Xenotransplantation Advisory Consultation in Geneva in
2005, 4 which was followed by the First WHO Global Consultation on Regulatory Requirements for Xenotransplantation Clinical Trials, whose recommendations were published as the Changsha communiqué in 2008. 5 In 2011, the Second WHO Global Consultation on Regulatory Requirements for Xenotransplantation Clinical Trials was held in Geneva focusing on xenotransplantation-associated infectious risk. 6, 7 The major progress in xenotransplantation research and development over the past few years motivated the international community to consider an update of these WHO-documents, and in particular to revisit the Principles and Recommendations to various parties including WHO itself, member states, and investiga- 
INTRODUC TION AND OPENING S E SS ION
The meeting was formally opened by Dr. Guogang Zhang, President of the Third Xiangya Hospital, The Central South University, and
Chairman of the Conference. Following his overview remarks and thanks to all participants from within China, Asia, and the rest of the world, he declared the meeting open. Dr. José Ramón Nuñez then provided a comprehensive introduction to the meeting, outlining the ongoing support from the WHO.
In his opening speech, he stated that it was his great pleasure and honor to attend on behalf of the WHO. On behalf of WHO, Dr.
Nuñez thanked the Hunan Authorities for hosting and supporting this important meeting, and also thanked the local and international organizers for their great organizational skills, and the major personal and institutional efforts to make it happen. Dr. Nuñez emphasized that for WHO, it is a priority as mandated by Member States to achieve Universal Health Coverage. Under this framework, it is the responsibility of WHO to give the best evidence-based response to patient's needs in many domains, ranging from disease prevention to transplantation. Shortage of available organs for transplant unfortunately is a reality these days throughout the world, and WHO supports all efforts globally to improve access to transplantation as well as to improve the quality of life and survival rates after transplant.
Xenotransplantation is an open door to potentially improve global access to transplantation provided ethical and safety measures are 
S E SS I ON I -UPDATE ON PROG RE SS IN SOLID ORG AN XENOTR ANS PL ANTATION (2 012-2 018)
Dr. Wayne J. Hawthorne opened this session with an introduction of participants and outline of the programme objectives. He outlined that there had been more than 40 invited participants with a total of 36 invited participants attending the meeting.
From these, there were a total of 25 speakers providing introduction and overview with updates of the latest innovations occurring in the xenotransplantation and regulatory fields. There were a total of 10 Chairs appointed for the various sessions of the meeting and also 6 group Rapporteurs/Chairs were elected for the comprehensive review of the Changsha Communiqué
Principles and Guidance documents. The focus was to critically review;
• New technologies,
• Donor animal genetics,
• Donor source herd holding requirements,
• Changing legislative frameworks (internationally),
• Definitions and processes for submitting clinical trial applications.
• Emergence of a number of potential xenotransplantation trials in islet cell, cornea, and kidney transplantation.
• Revisiting and prioritizing essential requirements for clinical trials in particular the safety and efficacy of such. 
, respectively, and then presented the aims of the 3rd meeting:
• To review the current status of xenotransplantation science and practice;
• To determine whether updates to the Changsha Communiqué's guidance to WHO, member state health regulatory authorities, and study investigators and/or sponsors of xenotransplantation trials are required; and
• To discuss and refine draft consensus guidelines for infectious disease surveillance, prevention and response, appropriate to support various imminent clinical xenotransplantation trials.
After presenting the programme of the present meeting, Dr.
Hawthorne concluded his introduction with the remark that this WHO Global Consultation has the prospect to strongly reconfirm the contribution by IXA and WHO to the regulation of xenotransplantation, and to provide a revision to WHO Mémoire on minimizing risks in xenotransplantation with a realistic potential for success in pilot clinical trials in selected patients.
S E SS I ON I-UPDATE ON PROG RE SS IN SOLID ORG AN XENOTR ANS PL ANTATION (2 012-2 018)
Dr. Peter Cowan chaired the introductory update and overview session where five international experts provided insight into current advances in the development of technologies for solid organ xenotransplantation and the regulatory frame works they are required to work within.
Dr. Muhammad Mohiuddin reviewed preclinical studies in heart xenotransplantation.
He outlined progress in the model of heterotopic pig heart transplantation in nonhuman primates, with the longest survival being over 900 days: this achievement required transgenic expression of the complement regulator CD46 (membrane cofactor protein) and thrombomodulin on the background of α1,3-galactosyltransferase gene knockout, in combination with costimulatory blockade using anti-CD40 antibody in the immunosuppressive cocktail. In longterm survivors, a major contribution to rejection was anti-non-Gal antibodies. He then reviewed the achievements in the orthotopic heart transplant model, with special focus on the recent Nature publication by the Munich group, reporting survival of 195 days (protocol study endpoint with functional graft). Among the lessons learned in this study was the need for optimal donor heart preservation before transplantation and use of anti-hypertensive drugs after transplantation, and control of graft growth by rapamycin. Dr.
Mohiuddin concluded with a perspective on clinically applicable drug regimens and an outlook on potential clinical conditions for which cardiac xenotransplantation may be justified. The key points that he felt necessary to move the field forward to clinical trials were as follows:
• Clinically approved immunosuppression for clinical translation;
• Experimental evidence for the benefit of additional genes;
• Ability of multiple centers to reliably reproduce the Munich results;
• Continuation of the dialog with regulatory agencies and commencement of a public awareness campaign. Regarding the coagulation cascade, this was illustrated for the efficacy of tissue factor pathway inhibitor, thrombomodulin, and endothelial protein C receptor. The model was used in evaluation of a large series of lungs from genetically modified pigs. In the model of in vivo lung transplantation into nonhuman primates, an increase in survival time over the last few years was noted, but survival rates still remain low (up to 30 days). Dr. Azimzadeh mentioned that injury of the vascular barrier function (leading to interstitial and airway edema) was among the significant remaining challenges.
Dr. Joseph Tector

Dr. Megan Sykes reviewed the current technologies and studies
in the development of tolerance and use of regulatory T cells. The major tolerance approaches remain focused on mixed chimerism and thymic transplantation. In rat-to-mouse models, mixed chimerism prepared in combination with non-myeloablative conditioning prevents both T cell-mediated and antibody-mediated rejection, and in addition induces tolerance of NK cells. These achievements in the rat-to-mouse model apply also to the pig-to-human combination, with evidence that central T-cell tolerance can be achieved through mixed pig/human hematopoietic chimerism. The possibility to tolerize B cells producing anti-pig antibodies may represent an alternative to generating knockout pigs being deficient in carbohydrate epitopes. However, mixed chimerism is short-lived in the pigto-baboon condition, with a major role for macrophages. To this end, transgenesis of CD47 (integrin associated protein) was introduced in pigs, resulting in increased porcine hematopoietic chimerism in baboons and prolonged porcine skin graft survival. This chimerism and skin graft survival was further prolonged when regulatory T cells were added to the protocol. The beneficial effect on tolerance using CD47-transgenic pig donors was also evident in other transplantation models. The efficacy of porcine thymus transplantation was first demonstrated in pig skin transplantation in mice, and further developed for vascularized thymic transplants in pig-to-baboon kidney transplantation using α1,3-galactosyltransferase gene knockout pigs. In this model, there was evidence for T-cell tolerance in in vitro assays.
Dr. Henk-Jan Schuurman gave an overview on regulatory aspects of xenotransplantation. The focus of regulatory agencies is on the full flow chart, that is, starting with the source pig herd and donor animal, continuing with the subsequent processing or manufacturing of the product, and ending with the monitoring of the patient.
Reference was made to recommendations in earlier WHO consultation meetings. The microbiological status of the source herd and donor animals, in particular, with regard to the different lists in the literature on excluded pathogens, and the requirements for barrier facilities. Dr. Schuurman noted that these requirements may be less for cell therapy products than for solid organs because of the time period in cell product manufacturing, with supporting data for a pig islet product. There is a broad regulation of cell therapy products, in contrast to that of organs: this is explained by the fact that a human organ in clinical transplantation is not a medicinal product. A proposal for release testing of a porcine xeno-organ is in preparation.
Archiving and documentation is required for clinical application of xenotransplantation products, and it is proposed to implement this in collaboration between public health institutes and trial sponsors. Dr. Henk-Schuurman chaired a summary discussion session based on the previous two sessions. This discussion focused on the benefit to balance the risk when a xenotransplantation product is clinically applied. A number of key opinion leaders in the audience were asked for their views, as a prelude to the discussion in subsequent sessions III-V. In general, the consensus was that the progress in preclinical efficacy of porcine kidney and heart transplantation in nonhuman primates, combined with better insights into the risk, in particular the microbial risk, has resulted in an increased window between anticipated efficacy and safety in the clinical setting. As an example, the advances in orthotopic heart transplantation in baboons presented by the Munich group were mentioned. 
S E SS I ON IIIA-THE REG UL ATORY ENVIRONMENT FOR XENOTR ANS PL ANTATION CLINIC AL TRIAL S
S E SS I ON IIIB-THE ROLE OF IX A AND WHO IN THE REG UL ATI ON OF XENOTR ANS PL ANTATION
Regulatory aspects: new or updated documents have been issued
in Europe and the United States, and there are relevant developments in establishing regulatory networks in Asian countries.
Biorepository:
there is ongoing discussion about materials to be archived, storage location, responsibility and financial support, and time of storage.
4.
Pig facilities: barrier conditions have been defined, but there is a central question about the definition of "clean" pigs.
Biomaterials and encapsulation:
there are a number of developments and innovations in islet encapsulation strategies, aiming to keep islets alive, prevent a destructive host response and assure practical surgical implantation.
Immunosuppression and tolerance induction:
there is the ongoing discussion (a) whether efficacy and safety should always be validated in a nonhuman primate model; (b) whether non-life-saving xenotransplantation products like kidney or cornea should be applied as new, innovative and possibly life-threatening regimens;
(c) whether any new drug (even not approved) can be considered in combination with a xenotransplantation product; and (d) on the translational value of efficacious strategies in an animal model.
Dr. Wayne Hawthorne established working groups to revisit
the guidelines post-Geneva. Dr. Hawthorne outlined the process to achieve the second and third aims of the meeting, that is, to assess whether updates to recommendations from previous WHO meetings were required; and to discuss and refine draft consensus amendments for infectious disease surveillance, prevention, and response, appropriate to support various imminent clinical xenotransplantation trials.
To this end, participants were divided into six working parties in relation to their particular areas of expertise, and a Chairperson and Rapporteur were voted as representatives for each of the groups;
Xenozoonosis
Regulatory
Biorepository
Transgenic Pig Facilities
Biomaterials and Encapsulation
Immunosuppression and Tolerance Induction
The task given to the defined groups was to review the guidelines ), and to propose any necessary amendments.
After discussion in each working party, the proposed amendments were presented and discussed in a plenary session. This was
followed by further refinement of the individual points raised. At the end of the meeting, these amendments were to be finalized and phrased as a proposed change in the respective recommendations to WHO, Member State health regulatory authorities, and study investigators and/or sponsors of xenotransplantation trials.
S E SS I ON V-SUMMARIE S FROM WORKING PARTIE S Main summaries regarding the Principles in the Changsha Communiqué
The working parties agreed unanimously on several modifications In order to better reflect the advanced state of preclinical xenotransplantation, Principle 1 has been amended to read that xenotransplantation, rather than "successful" xenotransplantation, has the potential to treat a wide range of serious diseases. To highlight the advances in xenotransplantation and the likelihood of clinical trials, the language of Principle 10 has been modified to indicate that equitable access should be given to "effective xenotransplantation therapies."
S E SS I ON VI-SUMMARY AND RE VIS I ON TO WHO MÉMOIRE ON MINIMIZING RIS K S IN XENOTR ANS PL ANTATION
The third and final day commenced with Dr. Peter Cowan revisiting and prioritizing essential requirements for clinical trials followed 
R E FE R E N C E S
A B S T R A C T S
A B S T R A C T S O F P R E S E N TAT
S E SSI O N I UPDATE ON PROG RE SS IN SOLID ORG AN XENOTR ANS PL ANTATI ON 2 012 2 018 P R E C L I N I C A L S TU D IE S | Preclinical studies: advancements in cardiac xenotransplantation
Muhammad M. Mohiuddin cardiac xenograft. Another development that has significantly helped xenotransplantation research is the availability of target specific antibodies, to block specific immune pathways, like CD40-CD40
ligand-mediated co-stimulation pathway, which have made a significant impact in the advancement of this field by suppressing rejection.
The specific role of these antibodies in preventing xenograft rejection will also be discussed. Dr Bruno Reichart' s group from Munich, Germany, has reported significant pig cardiac xenograft graft survival in orthotopic position and some of the information presented by this group at the transplantation meetings will be briefly discussed. Other major factors that have also been very helpful are: the utilization of novel monitoring methods for the graft function and improvements in methods to manage post-operative transplant animals, especially the ability to detect complications at an early stage with the ability to overcome these adverse effects.
Conclusion :
Finally, the impact of the above advancements in bringing xenotransplantation to the clinic and potential remaining hurdles for clinical translation will be reviewed. Liver xenotransplantation: It is likely that bridging trials where a patient with significant liver failure is transplanted with a pig liver to stabilize them until a human liver can be found will be the initial clinical application for liver xenotransplantation. Significant work needs to be done using newly available pig livers in a preclinical model before moving forward with clinical application. 
Preclinical studies: kidney and liver xenotransplantation
Preclinical studies: lung
Agnes Azimzadeh
Department of Surgery, Massachusetts General Hospital and Harvard Medical
Preclinical studies: regulatory aspects
Henk-Jan Schuurman Nevertheless, synthetic biomaterials are still being frequently used, with PEG being the most widely used synthetic biomaterial for islet encapsulation, though different encapsulation strategies have varying levels of success. Such strategies include assembling a thin layered PEG-lipid structure around the surface of islets and assembling a multilayer film around islets using biotin and streptavidin.
Due to the complications with islet encapsulation using synthetic materials, alginate encapsulation has risen in popularity due to its improved biocompatibility and stability, easy gelation process, and relatively low cost. Alginate has typically been the most popular microencapsulation material, due to its widespread availability and ease of production, although alginate endotoxin content and purity can vary from different manufacturers. The variation in alginate production and purification, in addition to the lack of research regarding the optimal transplantation site of islets and optimal donor strain and age, currently stand in the way of consistent success in transplanting alginate-encapsulated islets into hu- Commercially available immunosuppressants will be administered, and systemic infection prophylaxis will be performed according to the programme schedule. Data and safety monitoring board (DSMB)
is independently organized and will monitor the protocol adherence, patient eligibility, intensity of follow-up, and regular review of the data. After transplantation, each patient will be monitored at a specialized clinic to investigate safety up to 2 years and efficacy up to 1 year.
For islet xenotransplantation, two type 1 diabetes patients who meet selection and exclusion criteria will be enrolled. Primary purpose of this pilot trial is to confirm the safety of porcine islets.
Porcine islets will be isolated from SNU miniature pig and manufactured in a GMP-compliant facility and prepared to meet IXA islet product release criteria including sterility, potency, and viability.
Clinically applicable immunosuppression regimen modified from the one which has been developed from preclinical studies in nonhuman primates will be administered to warrant the safety of the patients.
Independent DSMB will examine the protocol adherence, patient eligibility, follow-up schedule, and resulting data. After transplantation, two patients will be monitored to investigate the safety of porcine islets up to 2 years and then followed by lifelong surveillance according to the law that will be supposed to be implemented by Korean government. 
Conclusion and/or recommendations :
SE SSION III UPDATE ON G M PI G S & FACILITIE S , PROP OS ED CLINIC AL
Pigs as a xenograft source animal and biosecurity in South Korea
Curie Ahn 
Monitoring and control of viral infections in xenotransplantation recipients
Minhua Luo and ongoing process validation, as well as the importance of measuring "activity" of the "product" (therapeutic effectiveness), and predicting consistent performance. Preclinical "proof-of-concept" data recommendations, the possible role of initial safety or dose escalation studies, and the need for contemporaneous or historical reference groups ("controls") were discussed.
In the general discussion, while emphasizing that every proposal must be considered individually, consensus was explored regarding results that IXA and FDA might consider "sufficient" to justify Together such measures are expected to provide a better care and protection to xenograft recipients and their close contacts, but also a higher safety profile to xenotransplantation procedures, with an ultimate net gain in terms of international public health. In this context, it is undeniable that a continued close collaboration and synergy between WHO and IXA will be of paramount importance to allow the development of a safe and successful application of clinical xenotransplantation.
